Last updated 2026-07-20
Portfolio
1
in our dataset
Rounds participated
1
Rounds led
0
Rounds' value
—
total disclosed, rounds participated
Stages
—
About
Lior Delgo is an Israeli entrepreneur with a history of founding disruptive technology companies. He co-founded FareChase, a travel search engine acquired by Yahoo! in 2004. Later, he co-founded VideoSurf in 2006, a video search technology company that utilized computer vision to analyze video content. VideoSurf was acquired by Microsoft in 2011 for approximately $70 million. Currently, Delgo is the Co-Founder and President of Globality, a Silicon Valley-headquartered tech company that provides an AI-powered platform for sourcing B2B services. Globality aims to digitally transform the sourcing industry by efficiently matching companies with suitable suppliers.
Portfolio · 1
Investment activity
1 portfolio exit on record.
Portfolio by sector
Media & Entertainment Technologies1
Undisclosed1
Q&A
- What is Lior Delgo's investment focus?
- Lior Delgo invests in companies across various sectors, including Media & Entertainment Technologies and other undisclosed areas. The portfolio includes companies like Social Studios and Silo.
- Which companies are notable in Lior Delgo's portfolio?
- Lior Delgo's portfolio includes Social Studios, a B2B company that transforms web content into promotional videos, and Silo, a social network for professionals.
- Has Lior Delgo had any exits from their portfolio?
- Yes, Lior Delgo had an exit in January 2015 with the acquisition of Social Studios by Vocativ.
- What is the typical investment stage for Lior Delgo?
- Lior Delgo primarily invests in the Seed stage, with two recorded investments at this stage.
- When did Lior Delgo make their most recent investment?
- Lior Delgo's most recent recorded investment was in April 2014.
- What is Lior Delgo's investment range?
- Lior Delgo's investment range is between $700K and $700K.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Radar intelligence
Patents
| EPO | 4 |
|---|